AVIR · Atea Pharmaceuticals Inc
United States · RS rating 49 · As of 2026-10-14
| Price | 4.63 USD |
|---|---|
| 1-day change | -7.0% |
| RS rating (overall / 1M / 3M / 12M) | 49 / 20 / 56 / 89 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 27 / 46 / 7 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -7.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +24.7% |
| Market cap (USD) | $439.8M |